CommentaryOpen Access

Commentary: NPHS2 mutations account for only 15% of nephrotic syndrome cases

Mara Sanches Guaragna1*, Anna Cristina GB Lutaif2, Vera MS Belangero2 Andréa T. Maciel-Guerra3,4, Gil Guerra-Junior4,5 and Maricilda P. De Mello1

1Center for molecular biology and Genetic engineering – CBMEG, State university of campinas, UNICAMP, Campinas, Brazil
2Integrated center of pediatric nephrology – CIN - School of medical sciences – FCM, State university of campinas, UNICAMP, Campinas, Brazil
3Department of medical genetics - School of medical sciences – FCM, State university of campinas, UNICAMP, Campinas, Brazil
4Interdisciplinary group for the Study of sex determination and differentiation – GIEDDS - State university of campinas, UNICAMP, Campinas, Brazil
5Pediatrics endocrinology, Department of pediatrics, School of medical sciences – FCM, State university of campinas, UNICAMP, Campinas, Brazil

Nephrotic syndrome (NS) represents one of the most common kidney conditions that affect children. It manifests as proteinuria, edema, hypoalbuminemia and hyperlipidemia. According to the response to standardized corticosteroid therapy, 80 to 90% of children that respond well to the treatment are classified as steroid sensitive (SSNS), whereas the remaining 10 to 20% that are unresponsive to the treatment are classified as steroid resistant (SRNS)1. NS is a highly heterogeneous condition and many SRNS cases remain idiopathic, although a fraction of them have a clear genetic etiology. The most frequent renal histologic feature of SRNS is focal segmental glomerulosclerosis (FSGS). Almost 40% of SRNS/FSGS children develop end-stage renal disease (ESRD) before adulthood and may receive kidney transplantation with 10 to 50% risk of FSGS recurrence in the allograft kidney2–4. Conversely, the post-transplant risk of proteinuria recurrence in patients with inherited forms of SRNS is only 1-2%5.

expressed in the visceral epithelial podocytes, specialized cells of the outer surface of the glomerular filtration barrier6. Two recent studies in large SRNS cohorts report a monogenic cause of the disease in approximately 30% of cases in whom mutations were found in one of those 50 genes7,8. Despite the increasing number of genes associated with SRNS, there are three that are frequently mutated in patients with early onset of the disease: NPHS1, NPHS2 and WT17–9. NPHS1 (OMIM *602716) mutations are typically associated with congenital nephrotic syndrome, with proteinuria onset before 3 months of age, although there are reports on mutations identified in childhood onset cases of SRNS10–12. NPHS1 encodes nephrin, an essential protein of the glomerular slit diaphragm formed between adjacent podocytes13. NPHS2 (OMIM *604766) mutations are responsible for 6-17% and 40% of sporadic and familial forms of SRNS in childhood, respectively, and encodes podocin, a close interactor of nephrin14–16. The third main gene associated with early onset SRNS is WT1 (OMIM *607102), which encodes a transcription factor that plays a key role during kidney and genital development. Dominant de novo mutations in exons 8-9 have been associated to 2 to 7% of sporadic cases of SRNS in childhood17.

Our publication “NPHS2 mutations account for only 15 % of nephrotic syndrome cases” was the first cohort study focusing on genetics of SRNS in Brazilian children. In this study we included 27 SRNS patients that enrolled from 2008 to 2013 in the reference public hospital of clinics from the South East region of Brazil18. The patients comprised seven unrelated familial cases and 20 sporadic cases with onset of proteinuria between 3 months and 18 years of age. We performed sequence analysis of the entire NPHS2 and NPHS1 genes and of exons 8 and 9 of the WT1 gene in all the patients. A genetic cause of the NS was identified in only four cases (4/27, 14.8%), two sporadic (2/20, 10%) and two familial (2/7, 28.5%) (Table 1). All variants considered as the cause of the NS in these patients were identified in NPHS2 gene. Therefore, mutations in NPHS1 and WT1 genes have not been identified in those patients. The sporadic patients were compound heterozygous for [p.Arg229Gln];[p.Ala284Val] and [p.Arg229Gln];[p.Glu310Lys] NPHS2 mutations, as indicated by the segregation of the variants in the family. Those results confirmed the autossomal recessive inheritance in both cases. The association of those mutations have been already described as the cause of SRNS by other groups19–22. In the case of the two familial cases, the heterozygosis for NPHS2 mutations were, respectively, [p.Arg229Gln (;) p.Ala284Val] and [p.Lys239Argfs*13 (;) p.Val260Glu]. We also identified the same combinations in the affected siblings, but we could not evaluate the segregation in these two families although we considered the compound heterozygosis as the most probable genotype. We are not aware if other members of the family have renal disease. The age at onset of NS in the two patients with the p.Arg229Gln variant along with the p.Ala284Val mutation was 12 and 13 years old, confirming a later onset of the disease as the result of this association21. One of them progressed to CKD and received kidney transplant with no FSGS recurrence. On the other hand, the other two familial cases presented NS symptoms with 1.2 and 2.2 years old and with no progress to ESRD yet.

Table 1:Clinical data from SRNS patients with NPHS2 variants



Age onset



Renal biopsyb

Renal transplant



Two heterozygous variants
P6 12 spo FSGS Yes [p.Ala284Val] ; [p.Arg229Gln]
P67 2.2 spo DMP No [p.Glu310Lys] ; [pArg229Gln]
P103 1.2 fam FSGS No [p.Lys239Argfs*13 (;) p.Val260Glu]
P154 13 fam FSGS No [p.Arg229Gln (;) p.Ala284Val]
One heterozygous variant
P111 3 spo FSGS No c.-164C>T
P68 4 spo CO No c.-196C>G
P85 6.11 spo CO Yes c.-537_531delCTTTTTT
P72 16 fam FSGS Yes p.Arg229Gln

aSpo: sporadic; Fam: familial;bFSGS:focal segmental glomerular sclerosis; DMP: diffuse mesangial proliferation; CO: complex = minimal change disease or diffuse mesangial proliferation or focal segmental glomerular sclerosis.

Our findings also included SRNS patients with only one heterozygous alteration in the NPHS2 gene: three sporadic cases presented promoter variants c.-164C>T, c.-196C>G and c.-537_-531delCTTTTTT and a familial case presented the p.Arg229Gln variant. Two of these patients progressed to ESRD and both received kidney transplant, although one of them presented FSGS recurrence post-transplant. Regarding promoter variants, Di Duca et al.23 studied regulatory elements in the NPHS2 promoter and described the c.-537_-531delCTTTTTT variant (rs146791300, MAF = 0.069; as a “functional polymorphism” that downregulated the gene expression of podocin by 85% when transfected in podocytes. Since there are no records of association of c.-164C>T and c.-196C>G variants with SRNS patients and our in-silico predictions indicated a possible creation of a new WT1 transcription binding site after c.-164C>T transition, we are investigating their role on podocin expression using reporter vector transfection assays in podocytes. For the familial case presenting the p.Arg229Gln, he and his father presented this variant and both had already received kidney transplant with no FSGS recurrence, clearly indicating a genetic background of their NS. Therefore, we performed whole exome sequencing (WES) for this family and the results will be published further.

Our paper’s main limitation was the sample small size. Approximately 200 patients with NS are routinely followed up in our service, one of the reference centers in Brazil; our 27 SRNS patients represent a frequency of 13.5% (27/200), which is in line with the reported worldwide frequency of 10-20% for this form of the condition. However, the sample is considered small for mutation frequency and epidemiological estimations16,24. An example of this limitation is the NPHS2 mutation rate – 28.5% - detected for our four out of seven familial cases. We cannot assure that the frequency described by us for the Brazilian population is lower then those described by others in different populations (~ 40%), since our cohort is not robust enough for making such comparisons. The Brazilian population is highly miscegenated and presents diverse regional features therefore our cohort from South East did not represent the entire country. The novelty of the work was the genetic study in Brazilian SRNS patients and the identification of a new frameshift mutation associated with SRNS.

Since we were able to identify the genetic origin of the NS only in 14.8% of our SRNS cases, our conclusion was that target-oriented next generation sequencing of glomerulopathy related genes is recommended to search for mutations in other genes related to SRNS in the remaining 74.2% patients. It is worth to mention that such studies are being carried out. Finally, the unequivocal molecular genetic diagnose and the correct establishment of genotype-phenotype correlation are essential because they can influence physicians’ decision on individual treatment, as patients carrying mutations can be spared the side effects of immunosuppressive therapy and ultimately can be considered for kidney transplantation from a living donor.

This work was supported by the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq - 478444/08-7 to G.G-J and 141072/2010 to MSG) and Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP - 2012/51109-0 to MPdeM).

  1. Benoit G, Machuca E, Antignac C. Hereditary nephrotic syndrome: a systematic approach for genetic testing and a review of associated podocyte gene mutations. Pediatr Nephrol. 2010 Sep; 25(9): 1621–32.
  2. Cheong HI, Han HW, Park HW, et al. Early recurrent nephrotic syndrome after renal transplantation in children with focal segmental glomerulosclerosis. Nephrol Dial Transplant. 2000; 15(1): 78–81.
  3. Smith JM, Stablein DM, Munoz R, et al. Contributions of the Transplant Registry: The 2006 Annual Report of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS). Pediatr Transplant. 2007; 11(4): 366–73.
  4. Ingulli E, Tejani A. Racial differences in the incidence and renal outcome of idiopathic focal segmental glomerulosclerosis in children. Pediatr Nephrol. 1991 Jul; 5(4): 393–7.
  5. Höcker B, Knüppel T, Waldherr R, et al. Recurrence of proteinuria 10 years post-transplant in NPHS2-associated focal segmental glomerulosclerosis after conversion from cyclosporin A to sirolimus. Pediatr Nephrol. 2006; 21(10): 1476–9.
  6. Pavenstädt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev. 2003 Jan; 83(1): 253–307.
  7. Sadowski CE, Lovric S, Ashraf S, et al. A Single-Gene Cause in 29.5% of Cases of Steroid-Resistant Nephrotic Syndrome. J Am Soc Nephrol. 2014; 26(6): 1279–89.
  8. Bierzynska A, McCarthy HJ, Soderquest K, et al. Genomic and clinical profiling of a national nephrotic syndrome cohort advocates a precision medicine approach to disease management. Kidney Int. 2017.
  9. Hinkes BG, Mucha B, Vlangos CN, et al. Nephrotic syndrome in the first year of life: two thirds of cases are caused by mutations in 4 genes (NPHS1, NPHS2, WT1, and LAMB2). Pediatrics. 2007 Apr; 119(4): e907-19.
  10. Kestilä M, Lenkkeri U, Männikkö M, et al. Positionally cloned gene for a novel glomerular protein--nephrin--is mutated in congenital nephrotic syndrome. Mol Cell. 1998 Mar; 1(4): 575–82.
  11. Schoeb DS, Chernin G, Heeringa SF, et al. Nineteen novel NPHS1 mutations in a worldwide cohort of patients with congenital nephrotic syndrome (CNS). Nephrol Dial Transplant. 2010 Sep; 25(9): 2970–6.
  12. Philippe A, Nevo F, Esquivel EL, et al. Nephrin mutations can cause childhood-onset steroid-resistant nephrotic syndrome. J Am Soc Nephrol. 2008; 19(10): 1871–8.
  13. Ruotsalainen V, Ljungberg P, Wartiovaara J, et al. Nephrin is specifically located at the slit diaphragm of glomerular podocytes. Proc Natl Acad Sci U S A. 1999 Jul 6; 96(14): 7962–7.
  14. Huber TB, Simons M, Hartleben B, et al. Molecular basis of the functional podocin-nephrin complex: mutations in the NPHS2 gene disrupt nephrin targeting to lipid raft microdomains. Hum Mol Genet. 2003 Dec 15; 12(24): 3397–405.
  15. Karle SM, Uetz B, Ronner V, et al. Novel mutations in NPHS2 detected in both familial and sporadic steroid-resistant nephrotic syndrome. J Am Soc Nephrol. 2002 Feb; 13(2): 388–93.
  16. Weber S, Gribouval O, Esquivel EL, et al. NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence. Kidney Int. 2004 Aug; 66(2): 571–9.
  17. Lipska BS, Ranchin B, Iatropoulos P, et al. Genotype-phenotype associations in WT1 glomerulopathy. Kidney Int. 2014; 85(5): 1169–78.
  18. Guaragna MS, Lutaif ACGB, Piveta CSC, et al. NPHS2 mutations account for only 15% of nephrotic syndrome cases. BMC Med Genet. 2015; 16: 88.
  19. Ruf RG, Lichtenberger A, Karle SM, et al. Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol. 2004 Mar; 15(3): 722–32.
  20. Machuca E, Hummel A, Nevo F, et al. Clinical and epidemiological assessment of steroid-resistant nephrotic syndrome associated with the NPHS2 R229Q variant. Kidney Int. 2009 Apr; 75(7): 727–35.
  21. Tsukaguchi H, Sudhakar A, Le TC, et al. NPHS2 mutations in late-onset focal segmental glomerulosclerosis: R229Q is a common disease-associated allele. J Clin Invest. 2002 Dec; 110(11): 1659–66.
  22. K Tory, DK Menyhárd, F Nevo, et al. Mutation-dependent recessive inheritance in NPHS2-associated steroid-resistant nephrotic syndrome Beyond Mendel’s laws. Eur J Hum Genet. 2013; 21, Supple(C19.4): 50.
  23. Di Duca M, Oleggini R, Sanna Cherchi S, et al. Cis and trans regulatory elements in NPHS2 promoter: implications in proteinuria and progression of renal diseases. Kidney Int. 2006 Oct; 70(7): 1332–41.
  24. Benoit G, Machuca E, Antignac C. Hereditary nephrotic syndrome: a systematic approach for genetic testing and a review of associated podocyte gene mutations. Pediatr Nephrol. 2010; 25(9): 1621–32.

Article Info

Article Notes

  • Published on: May 24, 2017


  • hypoalbuminemia
  • steroid resistant
  • focal segmental glomerulosclerosis


Mara Sanches Guaragna
Caixa Postal 6010 - CBMEG-UNICAMP - 13083-875 - Campinas-SP, Brasil,
Tel.: + 55 19 3521 1091; Fax: + 55 19 3521 1089;

© 2017 Mara Sanches Guaragna. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License.